S&P 500   5,041.43 (+0.38%)
DOW   37,950.27 (+0.52%)
QQQ   426.63 (+0.19%)
AAPL   167.62 (-0.23%)
MSFT   409.85 (-0.48%)
META   508.57 (+2.91%)
GOOGL   155.99 (+0.33%)
AMZN   181.52 (+0.13%)
TSLA   149.85 (-3.60%)
NVDA   856.78 (+1.96%)
AMD   155.85 (+1.19%)
NIO   4.01 (+2.56%)
BABA   69.29 (+0.68%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   113.00 (-2.86%)
GE   156.55 (+0.57%)
CGC   7.77 (+19.72%)
DIS   113.45 (+0.45%)
AMC   2.93 (-1.68%)
PFE   25.31 (-0.43%)
PYPL   62.51 (-1.19%)
XOM   118.73 (+0.08%)
S&P 500   5,041.43 (+0.38%)
DOW   37,950.27 (+0.52%)
QQQ   426.63 (+0.19%)
AAPL   167.62 (-0.23%)
MSFT   409.85 (-0.48%)
META   508.57 (+2.91%)
GOOGL   155.99 (+0.33%)
AMZN   181.52 (+0.13%)
TSLA   149.85 (-3.60%)
NVDA   856.78 (+1.96%)
AMD   155.85 (+1.19%)
NIO   4.01 (+2.56%)
BABA   69.29 (+0.68%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   113.00 (-2.86%)
GE   156.55 (+0.57%)
CGC   7.77 (+19.72%)
DIS   113.45 (+0.45%)
AMC   2.93 (-1.68%)
PFE   25.31 (-0.43%)
PYPL   62.51 (-1.19%)
XOM   118.73 (+0.08%)
S&P 500   5,041.43 (+0.38%)
DOW   37,950.27 (+0.52%)
QQQ   426.63 (+0.19%)
AAPL   167.62 (-0.23%)
MSFT   409.85 (-0.48%)
META   508.57 (+2.91%)
GOOGL   155.99 (+0.33%)
AMZN   181.52 (+0.13%)
TSLA   149.85 (-3.60%)
NVDA   856.78 (+1.96%)
AMD   155.85 (+1.19%)
NIO   4.01 (+2.56%)
BABA   69.29 (+0.68%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   113.00 (-2.86%)
GE   156.55 (+0.57%)
CGC   7.77 (+19.72%)
DIS   113.45 (+0.45%)
AMC   2.93 (-1.68%)
PFE   25.31 (-0.43%)
PYPL   62.51 (-1.19%)
XOM   118.73 (+0.08%)
S&P 500   5,041.43 (+0.38%)
DOW   37,950.27 (+0.52%)
QQQ   426.63 (+0.19%)
AAPL   167.62 (-0.23%)
MSFT   409.85 (-0.48%)
META   508.57 (+2.91%)
GOOGL   155.99 (+0.33%)
AMZN   181.52 (+0.13%)
TSLA   149.85 (-3.60%)
NVDA   856.78 (+1.96%)
AMD   155.85 (+1.19%)
NIO   4.01 (+2.56%)
BABA   69.29 (+0.68%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   113.00 (-2.86%)
GE   156.55 (+0.57%)
CGC   7.77 (+19.72%)
DIS   113.45 (+0.45%)
AMC   2.93 (-1.68%)
PFE   25.31 (-0.43%)
PYPL   62.51 (-1.19%)
XOM   118.73 (+0.08%)
Free Trial

Compare Stocks

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$284.31
-2.3%		$331.66
$261.59
▼
$489.36
$8.11B0.87199,066 shs191,390 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-0.71%-12.17%-12.79%-4.38%-39.31%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
4.6507 of 5 stars		3.44.00.04.21.83.31.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
2.80
Moderate Buy$468.0064.61% Upside

Current Analyst Ratings

Latest BIO, AURR, and BAV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeBuy ➝ Neutral$400.00 ➝ $365.00
2/16/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Price TargetBuy ➝ Buy$395.00 ➝ $420.00
2/16/2024
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Price TargetOutperform ➝ Outperform$484.00 ➝ $480.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.67B3.04$11.76 per share24.18$306.51 per share0.93

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-$637.32M-$21.49N/A24.81N/A-23.86%3.90%2.77%5/2/2024 (Estimated)

Latest BIO, AURR, and BAV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/15/2024Q4 2023
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.93$3.10+$0.17-$5.94$685.00 million$681.18 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.14
5.83
4.34

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
65.24%

Insider Ownership

CompanyInsider Ownership
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
17.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
8,03028.52 million23.65 millionOptionable

BIO, AURR, and BAV Headlines

SourceHeadline
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
zacks.com - April 18 at 11:06 AM
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
businesswire.com - April 18 at 9:00 AM
Bio-Rad Laboratories, Inc. (NYSE:BIO) Forecasted to Post Q1 2025 Earnings of $2.39 Per ShareBio-Rad Laboratories, Inc. (NYSE:BIO) Forecasted to Post Q1 2025 Earnings of $2.39 Per Share
americanbankingnews.com - April 18 at 2:56 AM
Bio-Rad Laboratories, Inc. (NYSE:BIO) to Post Q1 2025 Earnings of $2.39 Per Share, Zacks Research ForecastsBio-Rad Laboratories, Inc. (NYSE:BIO) to Post Q1 2025 Earnings of $2.39 Per Share, Zacks Research Forecasts
marketbeat.com - April 17 at 5:55 PM
Zacks Research Weighs in on Bio-Rad Laboratories, Inc.s Q1 2024 Earnings (NYSE:BIO)Zacks Research Weighs in on Bio-Rad Laboratories, Inc.'s Q1 2024 Earnings (NYSE:BIO)
americanbankingnews.com - April 17 at 1:22 AM
Bio-Rad (BIO) Hurt by Softness in BioPharma and CompetitionBio-Rad (BIO) Hurt by Softness in BioPharma and Competition
zacks.com - April 16 at 12:01 PM
Zacks Research Equities Analysts Reduce Earnings Estimates for Bio-Rad Laboratories, Inc. (NYSE:BIO)Zacks Research Equities Analysts Reduce Earnings Estimates for Bio-Rad Laboratories, Inc. (NYSE:BIO)
marketbeat.com - April 16 at 7:27 AM
Lecap Asset Management Ltd. Purchases New Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)Lecap Asset Management Ltd. Purchases New Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)
marketbeat.com - April 13 at 8:08 PM
Cell Lysis Cell Fractionation Market Size, Share, Growth Statistics, Latest Trends, and Forecast to 2024 to 2032Cell Lysis Cell Fractionation Market Size, Share, Growth Statistics, Latest Trends, and Forecast to 2024 to 2032
taiwannews.com.tw - April 13 at 8:01 AM
Unlock the Potential of Hydroxyapatite: 7.8% CAGR Market Opportunity in Medical ImplantsUnlock the Potential of Hydroxyapatite: 7.8% CAGR Market Opportunity in Medical Implants
fmiblog.com - April 13 at 8:01 AM
Raymond James & Associates Sells 21,649 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)Raymond James & Associates Sells 21,649 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)
marketbeat.com - April 12 at 4:18 AM
Bio-Rad and Alleghany Health Network partner for patients with solid tumour cancerBio-Rad and Alleghany Health Network partner for patients with solid tumour cancer
pharmatimes.com - April 11 at 11:29 PM
Bio-Rad and Allegheny Health Network Cancer Institute Collaborate to Advance Personalized Monitoring of Solid Tumor Cancers with Droplet Digital PCRBio-Rad and Allegheny Health Network Cancer Institute Collaborate to Advance Personalized Monitoring of Solid Tumor Cancers with Droplet Digital PCR
the-scientist.com - April 11 at 11:29 PM
Oncocyte, Bio-Rad Partner on Global Launch of Transplant AssayOncocyte, Bio-Rad Partner on Global Launch of Transplant Assay
marketwatch.com - April 11 at 6:28 PM
Oncocyte stock rallies 90% post-market on Bio-Rad partnershipOncocyte stock rallies 90% post-market on Bio-Rad partnership
seekingalpha.com - April 11 at 6:28 PM
Oncocyte and Bio-Rad Partner on Global Launch of Transplant AssayOncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
prismmediawire.com - April 11 at 5:44 PM
Bio-Rad Laboratories (NYSE:BIO) Stock Price Down 3.9%Bio-Rad Laboratories (NYSE:BIO) Stock Price Down 3.9%
marketbeat.com - April 11 at 1:48 PM
Allspring Global Investments Holdings LLC Has $53.64 Million Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)Allspring Global Investments Holdings LLC Has $53.64 Million Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)
marketbeat.com - April 11 at 6:58 AM
Bio-Rads Chief Operating Officer Andrew Last to RetireBio-Rad's Chief Operating Officer Andrew Last to Retire
businesswire.com - April 10 at 4:15 PM
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Recommendation of "Moderate Buy" from AnalystsBio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Recommendation of "Moderate Buy" from Analysts
americanbankingnews.com - April 8 at 3:10 AM
Bio-Rad Laboratories (NYSE:BIO) Downgraded by StockNews.com to "Hold"Bio-Rad Laboratories (NYSE:BIO) Downgraded by StockNews.com to "Hold"
marketbeat.com - April 5 at 11:10 PM
Q2 2024 Earnings Forecast for Bio-Rad Laboratories, Inc. Issued By Zacks Research (NYSE:BIO)Q2 2024 Earnings Forecast for Bio-Rad Laboratories, Inc. Issued By Zacks Research (NYSE:BIO)
marketbeat.com - April 4 at 8:49 AM
Global Clinical Microbiology Market Size To Worth USD 6.58 Billion By 2033 | CAGR of 4.49%Global Clinical Microbiology Market Size To Worth USD 6.58 Billion By 2033 | CAGR of 4.49%
finance.yahoo.com - April 3 at 7:24 PM
Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down to $328.72Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down to $328.72
marketbeat.com - April 3 at 2:54 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Bio-Rad Laboratories logo

Bio-Rad Laboratories

NYSE:BIO
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.